Spravato (Esketamine) provides hope for treatment-resistant depression when traditional antidepressants fail. MDDCare connects patients with trusted clinics across the USA, ensuring access to advanced, FDA-approved care alongside ongoing therapy.

Spravato (Esketamine) is an FDA-approved option for treatment-resistant depression, given only in certified clinics. MDDCare helps you find authorized providers, understand insurance rules, and access safe, effective care.

Major Depressive Disorder (MDD) is common, while Treatment-Resistant Depression (TRD) occurs when standard therapies aren’t enough. MDDCare connects patients with clinics offering advanced treatments like TMS and Spravato for better care options.